The weight-loss
market is, for now,
a two-horse race.
Patents, clinical data, and a pipeline of next drugs keep rivals at bay.
↓ scroll to read
✦ The bottom line
Lilly's moat is patents and pipeline. Tirzepatide is protected for years; trials show it beats rivals; and Lilly already has the next drugs — an oral pill and a triple-agonist — coming up behind it.
↓ the brief below
✦ Teach me
The legal head start
A patent gives a drugmaker years where no one else can sell a copy of its medicine. During that window, it can charge enough to recoup the billions spent on research. The deeper the pipeline of new drugs, the longer the head start lasts.
Wall Street calls this
Patent exclusivity
A drug company's moat isn't a brand — it's the patent clock plus what's next in the lab. Lilly is winning on both.
Feeding the moat · R&D spending
$3.5
B
Lilly poured $3.5B — 18% of revenue — into research this quarter (up 28%), funding the next generation that extends the lead before today's patents expire.
Spending on research only matters if it produces winners — and Lilly's has, for 150 years. The company practically invented the modern diabetes business, which gave it the science that became today's weight-loss blockbusters. Here's the throughline.
How the lead was built
1876
Colonel Eli Lilly founds the company in Indianapolis.
1923
Lilly commercializes the first insulin — a century in diabetes begins.
2022-23
Mounjaro (diabetes) then Zepbound (obesity) launch — tirzepatide arrives.
Now
An oral GLP-1 pill (Foundayo) is approved; a triple-agonist (retatrutide) is in trials.
The moat, extended
FDA approval of Foundayo (orforglipron) … the only approved GLP-1 pill that can be taken any time of day, without food and water restrictions … orforglipron delivered superior blood sugar control and weight loss compared to oral semaglutide in a head-to-head type 2 diabetes trial.
↳ A pill is far easier to scale than an injection, and beating the rival's drug head-to-head is exactly how Lilly keeps the two-horse race tilted its way.